1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Year: 2021
Type: article
Source: Annals of Oncology
Authors: S.J. Klempner, C. Sirard, J. Chao, V. Chiu, D. Mahalingam, H. Uronis, M. Kagey, J. Baum, F. Dayyani, J. Song, J. Wang, S. Iqbal, M. Tejani, M.B. Sonbol, A.J. Scott, Z. Wainberg, J.A. Ajani
Institutions: Massachusetts General Hospital, Leap Therapeutics, Inc. (United States), City Of Hope National Medical Center, City of Hope, Angeles Clinic and Research Institute, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Duke Medical Center, University of California, Irvine, UC Irvine Health, BeiGene (China), University of Southern California, USC Norris Comprehensive Cancer Center, AdventHealth Orlando, AdventHealth, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Arizona), University of Arizona Cancer Center, University of California, Los Angeles, UCLA Medical Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3202801715